Results 41 to 50 of about 12,611 (222)
Mean PWID and subpopulation PWID prevalence rates, 1992–2007.
, 2013 Mean PWID and subpopulation PWID prevalence rates, 1992–2007.
Hannah L. F. Cooper (398395) +8 more
core +1 more source
The Lancet Regional Health. Western Pacific, 2022 Summary: Background: In most low-to-middle-income countries, HIV control at the population level among people who inject drugs (PWID) remains a major challenge.
Huong Thi Duong +17 more
doaj +1 more source
1071. Social Determinants of health (SDOH) among PWID living with HCV [PDF]
Open Forum Infectious Diseases, 2020 Abstract Background Though people who inject drugs (PWID) represent the overwhelming majority of those living with HCV, most have not been treated. Many HCV+ PWID represent the most marginalized persons in society, often experiencing poverty and poor access to care.
Corro, Luis Gonzalez +5 more
openaire +1 more source
Distributions of age at acute infection, for PWID and non-PWID.
, 2015 Distributions of age at acute infection, for PWID and non-PWID.
Maznah Dahlui (625566) +5 more
core +1 more source
Therapy of chronic hepatitis C in people who inject drugs: focus on adherence
Harm Reduction Journal, 2021 Background Intravenous drug use (IVDU) represents the major factor of HCV transmission, but the treatment uptake among people who inject drugs (PWID) remains low owing to a false presumption of low efficacy.
Sona Frankova +5 more
doaj +1 more source
Reduction in PWID population size with OAT scale-up.
, 2019 Model projections of (A) PWID population size in year 10 and (B) relative reduction in PWID population size across 10 years after OAT scale-up (from baseline [mean 21%] to 40%, 50%, and 60% coverage among PWID).
Kora DeBeck (572736) +10 more
core +1 more source
Addiction, EarlyView.Abstract Background and aims Injection‐related bacterial infections represent a major but under‐recognised health issue among people who inject drugs (PWID). Harm reduction interventions (HRIs) like needle and syringe programmes (NSP) and opioid agonist treatment (OAT) could mitigate their burden.
Anthony Cousien +7 more
wiley +1 more source
Clinicosocial profile of people who inject drugs receiving opioid substitution therapy at New Delhi
Journal of Forensic Science and Medicine, 2023 Introduction: Injecting drug use is a public health concern due to its clinical, social, economic, and legal consequences. Objective: (1) To evaluate the prevalence of infections associated with injecting drug use; and (2) To assess the social profile ...
Alagarasan Naveen +3 more
doaj +1 more source
2081. Failing to PrEPare is PrEParing to Fail: Advocating for PWID PrEP Inclusion
Open Forum Infectious Diseases, 2022 Abstract Background The CDC recommends that PrEP be offered to anyone with a history of injection drug use, with a particular focus on those that have injected in the past 6 months, shared injection equipment, or have sexual risk factors. Yet, PrEP remains underutilized.
Amanda Barner +2 more
openaire +1 more source
HIV Medicine, EarlyView.Abstract Objectives Migrants account for a substantial proportion of people living with HIV in Europe, yet inequalities across the HIV care continuum remain insufficiently characterized. We examined migration‐related differences in HIV diagnosis, treatment initiation and retention in care in Greece.
Nikos Pantazis +31 more
wiley +1 more source